Company: NIVFW
Filing Date: 2025-08-22
Form Type: DRS
Source: 0001213900-25-079717
Chunk: 3

Company: NewGenIvf Group Ltd
Filing Date: 2025-08-22
Form: DRS
Chunk 3
---
 Ordinary Shares sold or issuable
to White Lion under the White Lion Purchase Agreement and are subject to the further limitations set forth in the White Lion Purchase
Agreement.

We are not selling any securities
under this prospectus and will not receive any of the proceeds from the sale of the Resale Shares by the Selling Securityholders. However,
we may receive gross proceeds of up to $500 million from the sale of our Class A Ordinary Shares to White Lion pursuant to the White Lion
Purchase Agreement. The actual proceeds from White Lion may be less than this amount, depending on the number of Class A Ordinary Shares
sold and the price at which the Class A Ordinary Shares are sold. In addition, we may receive proceeds from the conversion of the Additional
Notes, Exchange Notes, Warrants, New CB Initial Note which proceeds will be used for working capital and other general corporate purposes.

The Selling Securityholders
will pay all brokerage fees and commissions and similar expenses attributable to the sales of the Resale Shares. We will pay the expenses
(except brokerage fees and commissions and similar expenses) incurred in registering the Resale Shares, including legal and accounting
fees. See “Plan of Distribution.”

Our Class A Ordinary Shares
currently trade on The Nasdaq Capital Market under the symbol “NIVF.” The last reported closing price of our Class A Ordinary
Shares on August 21, 2025 was $1.67.

We qualify as a “foreign
private issuer,” as defined in Rule 405 under the U.S. Securities Act of 1933, as amended, or the Securities Act, thus we are eligible
for reduced public company reporting requirements, and are permitted to rely on certain exemptions from Nasdaq corporate governance rules.

NewGenIvf Group Limited (“NewGenIvf,”
“Company,” “our,” “we,” or “us”) is a British Virgin Islands holding company with our
operations conducted through our subsidiaries in the Cayman Islands (our wholly-owned subsidiary, NewGenIvf Limited) and in Asia (Hong
Kong, Thailand, Kyrgyzstan, and the Kingdom of Cambodia). Under this holding company structure, investors are purchasing equity interests
in NewGenIvf, a British Virgin Islands holding company, and obtaining indirect ownership interests in our Cayman Islands and Asian operating
subsidiaries. Substantially all of NewGenIvf’s operations and assets are based in Thailand, Cambodia and Kyrgyzstan. As a result,
its businesses and operations are subject to the changing economic